{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:18:50Z","timestamp":1791998330496,"version":"4.4.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.hlc.2025.08.009","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:05:32Z","timestamp":1757516732000},"page":"1050-1059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Connecting the Dots: Hepatic Steatosis as a Central Player in the Choreography of the Liver-Cardiovascular-Kidney-Metabolic Syndrome"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0246-3231","authenticated-orcid":false,"given":"Richard H.","family":"Goodheart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oyekoya T.","family":"Ayonrinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2025.08.009_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.hlc.2025.08.009_bib2","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.hlc.2025.08.009_bib3","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.hlc.2025.08.009_bib4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.hlc.2025.08.009_bib5","first-page":"691","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.hlc.2025.08.009_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Musso","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.hlc.2025.08.009_bib7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cgh.2023.09.018","article-title":"Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of 129 studies","volume":"22","author":"Chan","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.hlc.2025.08.009_bib8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000539371","article-title":"European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"17","year":"2024","journal-title":"Obes Facts"},{"key":"10.1016\/j.hlc.2025.08.009_bib11","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.ultrasmedbio.2024.03.014","article-title":"WFUMB guidelines\/guidance on liver multiparametric ultrasound. Part 2: guidance on liver fat quantification","volume":"50","author":"Ferraioli","year":"2024","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.hlc.2025.08.009_bib12","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.ultrasmedbio.2024.03.013","article-title":"WFUMB guideline\/guidance on liver multiparametric ultrasound: part 1. Update to 2018 guidelines on liver ultrasound elastography","volume":"50","author":"Ferraioli","year":"2024","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.hlc.2025.08.009_bib13","series-title":"World Health Statistics 2024: monitoring Health for the SDGs, Sustainable Development Goals","year":"2024"},{"key":"10.1016\/j.hlc.2025.08.009_bib14","article-title":"Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD \u2013 reconciling the present with the past","volume":"3","author":"Ayonrinde","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.hlc.2025.08.009_bib15","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2025.08.009_bib16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pcad.2024.10.012","article-title":"Cardiovascular-kidney-metabolic syndrome - an integrative review","volume":"87","author":"Kittelson","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.hlc.2025.08.009_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated burden of metabolic dysfunction\u2013associated steatotic liver disease in US adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.hlc.2025.08.009_bib18","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/jgh.15009","article-title":"Nonalcoholic fatty liver disease burden: Australia, 2019\u20132030","volume":"35","author":"Adams","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.hlc.2025.08.009_bib20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.5114\/ceh.2023.130744","article-title":"Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor","volume":"9","author":"Platek","year":"2023","journal-title":"Clin Exp Hepatol"},{"key":"10.1016\/j.hlc.2025.08.009_bib21","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/s41591-024-03223-z","article-title":"Integrating liver endpoints in clinical trials of cardiovascular and kidney disease","volume":"30","author":"Zannad","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.hlc.2025.08.009_bib22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/apt.16750","article-title":"Editorial: global liver fat accumulation and global health-towards a sustainable development goal","volume":"55","author":"Ayonrinde","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.hlc.2025.08.009_bib23","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3389\/fphar.2019.01568","article-title":"Role of endothelial dysfunction in cardiovascular diseases: the link between inflammation and hydrogen sulfide","volume":"10","author":"Sun","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.hlc.2025.08.009_bib24","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.3390\/cells11162511","article-title":"Endothelial cell dysfunction and nonalcoholic fatty liver disease (NAFLD): a concise review","volume":"11","author":"Nasiri-Ansari","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.hlc.2025.08.009_bib25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","article-title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review","volume":"23","author":"Zheng","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.hlc.2025.08.009_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/1573403X16666200618161942","article-title":"Endothelial dysfunction and coronary vasoreactivity \u2013 a review of the history, physiology, diagnostic techniques, and clinical relevance","volume":"17","author":"Gunawardena","year":"2021","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.hlc.2025.08.009_bib27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s00428-006-0176-7","article-title":"Atherosclerosis research from past to present\u2014on the track of two pathologists with opposing views, Carl Von Rokitansky and Rudolf Virchow","volume":"449","author":"Mayerl","year":"2006","journal-title":"Virchows Arch"},{"key":"10.1016\/j.hlc.2025.08.009_bib28","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society consensus panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2025.08.009_bib29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1475-2891-14-6","article-title":"Role of homocysteine in the development of cardiovascular disease","volume":"14","author":"Ganguly","year":"2015","journal-title":"Nutr J"},{"key":"10.1016\/j.hlc.2025.08.009_bib30","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.3748\/wjg.v29.i25.3999","article-title":"Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis","volume":"29","author":"Pal","year":"2023","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.hlc.2025.08.009_bib31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/metabo14030153","article-title":"Interleukins: pathogenesis in non-alcoholic fatty liver disease","volume":"14","author":"Rafaqat","year":"2024","journal-title":"Metabolites"},{"key":"10.1016\/j.hlc.2025.08.009_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102870","article-title":"TNF\u03b1 is a key trigger of inflammation in diet-induced non-obese MASLD in mice","volume":"66","author":"Burger","year":"2023","journal-title":"Redox Biol"},{"key":"10.1016\/j.hlc.2025.08.009_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1469492","article-title":"Drivers of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: the threats of oxidative stress","volume":"11","author":"Minetti","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.hlc.2025.08.009_bib34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","author":"Francque","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.hlc.2025.08.009_bib35","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1053\/j.gastro.2020.02.020","article-title":"Metabolic inflammation-A role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease?","volume":"158","author":"Gehrke","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hlc.2025.08.009_bib36","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: a clinical review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.hlc.2025.08.009_bib37","first-page":"93","article-title":"Role of perturbated hemostasis in MASLD and its correlation with adipokines","volume":"14","author":"Pezzino","year":"2024","journal-title":"Life (Basel)"},{"key":"10.1016\/j.hlc.2025.08.009_bib38","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/jcm14020428","article-title":"The triad of risk: linking MASLD, cardiovascular disease and type 2 diabetes; from pathophysiology to treatment","volume":"14","author":"Michalopoulou","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.hlc.2025.08.009_bib39","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.14309\/ajg.0000000000003169","article-title":"TM6SF2 -rs58542926 genotype has opposing effects on incidence of hepatic and cardiac events in a community cohort","volume":"120","author":"Chen","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.hlc.2025.08.009_bib40","article-title":"Steatotic liver disease in younger adults is associated with altered gut microbiology","volume":"45","author":"Tashkent","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.hlc.2025.08.009_bib41","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/CIRCRESAHA.120.316242","article-title":"Gut microbiota and cardiovascular disease","volume":"127","author":"Witkowski","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.hlc.2025.08.009_bib42","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/hep.24097","article-title":"Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease","volume":"53","author":"Ayonrinde","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.hlc.2025.08.009_bib43","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/apt.17096","article-title":"Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000\u20132021","volume":"56","author":"Li","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.hlc.2025.08.009_bib44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/jgh.12666","article-title":"Childhood adiposity trajectories and risk of nonalcoholic fatty liver disease in adolescents","volume":"30","author":"Ayonrinde","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.hlc.2025.08.009_bib45","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","volume":"64","author":"Vos","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.hlc.2025.08.009_bib46","article-title":"Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents","volume":"2","author":"Chin","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.hlc.2025.08.009_bib47","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/hep.26495","article-title":"Importance of cardiometabolic risk factors in the association between nonalcoholic fatty liver disease and arterial stiffness in adolescents","volume":"58","author":"Huang","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.hlc.2025.08.009_bib48","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/gutjnl-2022-328105","article-title":"Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease","volume":"72","author":"Simon","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.hlc.2025.08.009_bib49","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.14309\/ajg.0000000000003278","article-title":"Longitudinal associations between metabolic dysfunction-associated steatotic liver disease and subclinical cardiovascular measures in Chinese children","volume":"120","author":"Qiao","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.hlc.2025.08.009_bib50","article-title":"Non-alcoholic fatty liver disease in women \u2013 current knowledge and emerging concepts","volume":"5","author":"Eng","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.hlc.2025.08.009_bib51","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps","volume":"70","author":"Lonardo","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.hlc.2025.08.009_bib52","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.cgh.2021.11.007","article-title":"Metabolic dysfunction-associated fatty liver disease and subsequent development of adverse pregnancy outcomes","volume":"20","author":"Lee","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.hlc.2025.08.009_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1012244","article-title":"Progression to type 2 diabetes mellitus after gestational diabetes mellitus diagnosed by IADPSG criteria: systematic review and meta-analysis","volume":"13","author":"Juan","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.hlc.2025.08.009_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002488","article-title":"Increased risk of ischemic heart disease, hypertension, and type 2 diabetes in women with previous gestational diabetes mellitus, a target group in general practice for preventive interventions: a population-based cohort study","volume":"15","author":"Daly","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.hlc.2025.08.009_bib55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/liv.15725","article-title":"Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage","volume":"44","author":"Clayton-Chubb","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.hlc.2025.08.009_bib56","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2306192","article-title":"The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis","volume":"56","author":"Lv","year":"2024","journal-title":"Ann Med"},{"key":"10.1016\/j.hlc.2025.08.009_bib57","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1038\/s41598-025-89293-6","article-title":"Metabolic dysfunction-associated steatotic liver disease increases cardiovascular disease risk in young adults","volume":"15","author":"Chung","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.hlc.2025.08.009_bib58","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jcmg.2024.06.012","article-title":"Hepatic steatosis and high-risk coronary plaque: a systematic review","volume":"17","author":"Sukudom","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.hlc.2025.08.009_bib59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13098-025-01577-z","article-title":"Correlation between metabolic dysfunction-associated steatotic liver disease and subclinical coronary atherosclerosis in Eastern China","volume":"17","author":"Ma","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.hlc.2025.08.009_bib60","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.amjcard.2017.07.107","article-title":"Effect of nonalcoholic fatty liver disease on in-hospital and long-term outcomes in patients with ST\u2013segment elevation myocardial infarction","volume":"120","author":"Keskin","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hlc.2025.08.009_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155370","article-title":"Hepatic fat as a novel marker for high-risk coronary atherosclerotic plaque features in familial hypercholesterolaemia","volume":"139","author":"Huangfu","year":"2023","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.hlc.2025.08.009_bib62","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13098-023-01102-0","article-title":"Metabolic dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study","volume":"15","author":"Wei","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.hlc.2025.08.009_bib63","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2022-327672","article-title":"Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals","volume":"72","author":"Mantovani","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.hlc.2025.08.009_bib64","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.3567","article-title":"Metabolic dysfunction-associated steatotic liver disease is associated with increased risks of heart failure","volume":"27","author":"Chang","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hlc.2025.08.009_bib65","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12072-022-10319-6","article-title":"Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis","volume":"16","author":"Yong","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.hlc.2025.08.009_bib66","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/eurjpc\/zwab212","article-title":"Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"29","author":"Alon","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.hlc.2025.08.009_bib67","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1038\/s41598-025-90667-z","article-title":"Metabolic dysfunction associated steatotic liver disease is associated with atrial fibrillation recurrence following cryoballoon ablation","volume":"15","author":"Wang","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.hlc.2025.08.009_bib68","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.hlc.2025.08.009_bib69","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035804","article-title":"Reversal of nonalcoholic fatty liver disease reduces the risk of cardiovascular disease among Korean","volume":"102","author":"Oh","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.hlc.2025.08.009_bib70","doi-asserted-by":"crossref","first-page":"440","DOI":"10.5009\/gnl18382","article-title":"Improvement of nonalcoholic fatty liver disease reduces the risk of type 2 diabetes mellitus","volume":"13","author":"Cho","year":"2019","journal-title":"Gut Liver"},{"key":"10.1016\/j.hlc.2025.08.009_bib71","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3350\/cmh.2023.0384","article-title":"Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: a systematic review and meta-analysis","volume":"30","author":"Hwang","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.hlc.2025.08.009_bib72","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.08.009_bib73","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.08.009_bib74","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","article-title":"Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis","volume":"12","author":"Usman","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.hlc.2025.08.009_bib75","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.hlc.2025.08.009_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2024.100018","article-title":"Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: current and emerging therapeutic options","volume":"77","author":"Zhang","year":"2025","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.hlc.2025.08.009_bib77","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950625016002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950625016002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:31:19Z","timestamp":1759793479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950625016002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":74,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1443950625016002"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2025.08.009","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Connecting the Dots: Hepatic Steatosis as a Central Player in the Choreography of the Liver-Cardiovascular-Kidney-Metabolic Syndrome","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2025.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).","name":"copyright","label":"Copyright"}]}}